Association of Serum C-Reactive Protein Level and Treatment Duration in Acute Cholecystitis Patients Treated Conservatively

Review began 01/28/2022
Review ended 02/07/2022
Published 02/12/2022

© Copyright 2022

Vural et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Selahattin Vural¹, Ismail Aydin¹, Tugrul Kesicioglu¹

1. General Surgery, Giresun University Faculty of Medicine, Giresun, TUR

Corresponding author: Selahattin Vural, drselahattinvural@hotmail.com

Abstract

Background: Acute cholecystitis (AC) is one of the most common gastrointestinal diseases that require hospitalization and surgical treatment. The treatment of the disease depends upon the severity of the disease and the patients' medical status.

Objective: In this study, we aimed to investigate if there is an association between the serum C-reactive protein (CRP) value and treatment response and the duration and length of hospital stay in AC patients who are treated conservatively.

Methodology: The medical records of all patients with the diagnosis of AC who were treated with conservative management were included in the study. The demographic and laboratory data including CRP level at first admission to hospital, length of hospital stay, and complications during the conservative treatment were obtained from the patients' records. Patients were divided into two groups according to the treatment response and length of hospital stay. Group 1 patients were defined as patients who responded to the medical treatment in less than three days, and Group 2 patients were defined as patients who did not respond to the medical treatment in three days and stayed at the hospital for more than three days.

Results: We identified 101 patients with AC treated medically. Mean age (51.3 ± 16.3 , 59.5 ± 15.7 ; $p = 0.013$), total leukocyte count (11.8 ± 4.4 , 8.2 ± 2.8 ; $p = 0.0005$), and CRP value (19.3 ± 13.9 , 9.6 ± 5.2 ; $p = 0.0003$) were higher in Group 2 compared to Group 1. Correlation analyses demonstrated a significant positive association between the length of hospital stay, total leukocyte count ($r = 0.35$; $p = 0.0002$), and CRP value ($r = 0.59$; $p = 0.0004$).

Conclusion: We found that CRP level is associated with treatment duration and hospital stay in AC patients. However, large-scale, prospective further studies are needed to confirm our results and to determine whether CRP levels can be used to discriminate which patient would benefit from medical treatment.

Categories: Emergency Medicine, General Surgery, Infectious Disease

Keywords: prognosis, medical, treatment, crp, acute cholecystitis

Introduction

Acute cholecystitis (AC) defined by right upper quadrant pain, presence of Murphy's sign, fever, elevated white blood cell count (WBC), and C-reactive protein (CRP) is one of the most common gastrointestinal diseases that require hospitalization and surgical treatment [1]. Obstruction of the bile duct mostly due to a gallstone or a tumor leads to biliary stenosis and results in inflammation and infection in the biliary system. Delay in treatment causes progression to severe disease, which is generally defined as inflammation, empyema, gangrene or perforation of gallbladder, adhesions, or difficulty in dissecting Calot's triangle [2]. The treatment of AC depends on the severity of the disease and the patient's general status [3]. Cholecystectomy which is mostly performed by laparoscopy or conservative treatment is considered the treatment of choice in patients presenting with AC [4,5].

CRP is a nonspecific acute-phase reactant protein synthesized in the liver, which is used as a systemic marker for inflammation. It correlates with the severity of infection and inflammation in most of the acute inflammatory diseases [6]. In recent studies, CRP is also found to be associated with the severity of AC [7].

Although there are studies showing an association between serum inflammation markers and severity of AC, there is no data about the serum CRP level and the treatment duration and length of the hospital stay of AC patients treated with conservative management. The aim of this study was to determine if clinical variables and serum inflammatory markers such as WBC and CRP values in the first admission of patients with AC are related to the treatment response and the duration and length of the hospital stay.

How to cite this article

Vural S, Aydin I, Kesicioglu T (February 12, 2022) Association of Serum C-Reactive Protein Level and Treatment Duration in Acute Cholecystitis Patients Treated Conservatively. Cureus 14(2): e22146. DOI 10.7759/cureus.22146

Materials And Methods

This case-control study was conducted at Giresun University, Prof Dr. A. İlhan Özdemir Education and Research Hospital in Turkey. The medical records of all patients presenting with abdominal pain to the emergency clinic between 2015 and 2018 were evaluated, and patients with a diagnosis of AC and those who were treated with conservative management were included in the study. The institutional review board of Ordu Üniversitesi Klinik Araştırmalar Etik Kurul approved our study (Approval number: 2020/198).

The diagnosis of AC was defined as the presence of abdominal pain in the right upper quadrant and positive Murphy's sign with systemic signs of inflammation (fever and/or shaking chills or laboratory data as evidence of inflammatory response) or cholestasis (jaundice or laboratory data as abnormal liver function tests) and possibly with radiologic findings as biliary dilatation or evidence of the etiology on imaging (stricture, stone, stent, etc.) according to the Tokyo Guideline (TG) 2018 [8]. The severity of the disease was assessed with the severity grading criteria of TG 2018. Patients who managed with early and urgent cholecystectomy, Grade 3 disease, and malignancy, were excluded from the study.

Patients' demographic data including age, body mass index (BMI), sex, comorbidities (diabetes mellitus, hypertension, thyroid disease, and romatological disease), and the laboratory data of routine serum hemoglobin level, WBC, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and CRP level at first admission to the hospital were obtained from the patient records. We also recorded the length of hospital stay during treatment and the complications during conservative treatment that were defined as any event requiring additional treatment.

The standard conservative treatment regimen was intravenous fluid and electrolyte infusion, electrolyte correction, and antimicrobial therapy with a combination of intravenous metronidazole and cephalosporin with analgesics in the study population during the study period, and if the patients' physical status was appropriate for surgery, cholecystectomy was offered three months after the first AC attack.

The Statistical Package for the Social Sciences (SPSS) program version 15.0 (SPSS Inc., Chicago, IL) was used for analysis. The results were presented as means $\pm$ standard deviation (SD) values. Kolmogorov-Smirnov test was used for normality of data distribution and variance homogeneity. The parameters with a normal distribution were compared between the groups by the student's t-test. Parameters with non-normal distribution were compared between the groups by non-parametric tests such as the Mann-Whitney U test or the Fisher's exact test.

Correlation analyses between parameters were made by Pearson's or Spearman's correlation tests depending on the distribution of data; a p-value of <0.05 was considered statistically significant.

Results

A total of 108 patients diagnosed with cholecystitis at first hospital admission and treated with conservative treatment during the study period were included in the study. Conservative treatment included bowel rest and intravenous administration of broad-spectrum antibiotics and fluids. Seven patients showed worsening of clinical signs and laboratory results during follow-up, and emergency cholecystectomy was performed and excluded from the study. A total of 101 patients (93.5%) showed resolution of symptoms and were discharged successfully.

In our study population, the mean age was 56.0 ± 16.4 , 56 patients (55.4%) were men, and 45 (44.6%) were women. The mean length of hospital stay was 5.5 ± 3.7 days, and the mean CRP value was 15.2 ± 12.06 . There was no mortality in our study population. Demographic data and laboratory test results of our study population were shown in Table 1.

Variables	n
Age (y), mean (SD)	56.0 ± 16.4
Sex, n (%)	
Male	56 (55.4)
Female	45 (44.6)
Comorbidity	
Yes	19 (18.8)
No	82 (81.2)
BMI (kg/m ²)	27.6 ± 3.3
Hemoglobin (gr/dl)	13.4 ± 1.8
WBC x 10 ³ mL	10.3 ± 4.2
Total bilirubin (mg/dl)	1.46 ± 1.30
ALT (IU/L)	51.7 ± 50.2
AST (IU/L)	57.9 ± 62.5
Amylase	58.5 ± 28.9
CRP (mg/dL)	15.2 ± 12.0
Length of hospital stay (d)	5.5 ± 3.7

TABLE 1: Demographic and laboratory characteristics of the study population

Data is expressed as mean ± SD.

BMI: Body mass index; WBC: white blood cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: C-reactive protein.

Patients were divided into two groups according to treatment response and the length of hospital stay. We defined Group 1 patients as patients who responded to medical treatment in less than three days and stayed at the hospital for one to three days, and Group 2 patients were defined as patients who did not respond to the medical treatment in three days and stayed at the hospital for more than three days. Table 2 summarizes the comparative analysis of Group 1 and Group 2 patients in terms of demographic, clinical, and laboratory data at the first hospital admission. Mean age (51.3 ± 16.3 , 59.5 ± 15.7 ; $p = 0.013$), total leukocyte count (11.8 ± 4.4 , 8.2 ± 2.8 ; $p = 0.0005$), and CRP value (19.3 ± 13.9 , 9.6 ± 5.2 ; $p = 0.0003$) were higher in Group 2 patients compared to Group 1 patients.

Variables	Group 1 (n = 43)	Group 2 (n = 58)	P-value
Age (y), mean (SD)	51.3 ± 16.3	59.5 ± 15.7	0.013
Sex, n (%)			
Male	27 (62.8)	30 (51.7)	0.22
Female	16 (37.2)	28 (48.3)	
Comorbidity, n (%)			
Yes	7 (16.3)	12 (20.7)	0.38
No	36 (83.7)	46 (79.3)	
BMI (kg/m ²)	27.1 ± 2.7	27.5 ± 3.6	0.23
Hemoglobin (gr/dl)	13.1 ± 1.9	13.5 ± 1.7	0.28
WBC x 10 ³ mL	8.2 ± 2.8	11.8 ± 4.4	0.0005
Total bilirubin(mg/dl)	1.17 ± 0.8	1.67 ± 1.5	0.06
ALT (U/L)	37.1 ± 28.3	48.6 ± 32.9	0.07
AST (U/L)	39.8 ± 34.0	51.0 ± 43.9	0.17
Amylase	58.1 ± 23.7	58.8 ± 32.5	0.89
CRP (mg/dL)	9.6 ± 5.2	19.3 ± 13.9	0.0003
Length of hospital stay (d)	2.5 ± 1.07	7.6 ± 3.0	0.0005

TABLE 2: Demographic and laboratory characteristics of Group 1 and Group 2 patients

Data is expressed as mean ± SD.

BMI: Body mass index; WBC: white blood cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CRP: C-reactive protein.

To evaluate a possible association between the serum total leukocyte count, CRP value, and length of hospital stay, we used bivariate correlation analyses. Correlation analyses demonstrated a significant positive association between the length of hospital stay and total leukocyte count ($r = 0.35$; $p = 0.0002$) and CRP value ($r = 0.59$; $p = 0.0004$) (Figures 1, 2).

FIGURE 1: Correlation between the serum WBC level and length of hospital stay in patients with AC (p = 0.0004)

WBC: White blood cells; AC: acute cholecystitis.

FIGURE 2: Correlation between the serum CRP level and length of hospital stay in patients with AC ($p = 0.0002$)

CRP: C-reactive protein; AC: acute cholecystitis.

Discussion

In this study, we found that serum inflammation markers such as WBC and CRP at the first hospital admission were significantly lower in patients who respond to medical treatment earlier, and we have reported a positive and significant correlation between the serum CRP and WBC levels and the length of hospital stay in patients presenting with mild and moderate AC managed with conservative treatment. To the best of our knowledge, this is a rare study that evaluated and demonstrated an association between the CRP level and the length of hospital stay in AC with conservative treatment.

AC is a common disease with a high socio-economic impact. It is the sixth most common gastrointestinal disease diagnosed in emergency clinics and the second most common cause of hospitalization in the United States [9]. When AC is diagnosed, clinical management depends on the disease severity and patient's status [5]. Laparoscopic cholecystectomy, percutaneous cholecystostomy, or conservative treatment are treatment modalities for patients with AC [10]. While cholecystectomy in patients with AC prevents the later recurrence of the disease, it has an approximately 15% complication rate. Conservative treatment prevents surgical complications; however, it may cause recurrent disease, or living with the gallbladder may cause progression to severe disease [11]. Although early laparoscopic cholecystectomy is recommended if the patient is suitable for surgery in Grade 1 disease in TG 2018 [5], there is a wide variation due to patient- or hospital-related factors in the management of patients presenting with AC worldwide.

Agrawal et al. showed 100% treatment responses with antibiotic treatment in patients with mild AC in 25 patients [12]. In another study, Gutt et al. found 92% treatment responses in their study [13]. Recently, Loozen et al. reported that 87% of patients with AC responded to the conservative treatment that included bowel rest and broad-spectrum antibiotics without the need for surgery or other intervention in a systematic review [11]. In our study, we found that 93.5% of our patients responded to medical treatment and were discharged successfully similar to the literature.

TG defined the severity of AC as Grades 1 to 3 according to clinical findings, physical examination, laboratory tests, and imaging methods. In Grade 1 disease, there are mild inflammatory changes in the gallbladder; in Grade 2 disease, there is a moderate inflammation without organ dysfunction; however, in Grade 3 disease, there is a severe inflammation with organ dysfunction [8]. The determination of the severity of disease in patients with AC in the first admission is important for choosing the treatment modality and determining the prognosis [14]. CRP is used only as a diagnostic criterion but not for severity assessment in this guideline.

CRP is an acute-phase reactant synthesized in the liver that increases in inflammatory diseases [6], and

when levels to 10 mg/L are usually thought to be clinically insignificant, levels of 100 mg/L and higher are considered to be associated with tissue necrosis [15,16]. Studies in the recent literature have shown that increased systemic inflammatory markers are associated with severity and poor prognosis with many types of diseases such as cancer [17], acute appendicitis [18], acute heart failure [19], and sepsis [20].

Several studies also showed that serum CRP level was associated with AC [21,22] and found to be a predictive factor in the assessment of the severity of the disease [7,23]. Mok et al. observed that patients with gangrenous cholecystitis had a significantly higher CRP value, and CRP level > 200 mg/dL was found to be having a 50% positive and 100% negative predictive value for gangrenous cholecystitis with 100% sensitivity and 87.9% specificity [22]. Nikfarjam et al. reported that CRP value > 94 mg/L is a predictive factor for gangrenous cholecystitis [7]. Sato et al. found that serum neutrophil-lymphocyte ratio (NLR) and CRP/albumin ratio are significantly elevated in patients with AC with Grade 2 and Grade 3 diseases, and these markers could independently predict the Grade 2 and Grade 3 diseases [24]. Gurbulak et al. showed that the serum CRP level was a strong predictor in classifying different grades of the disease according to TG 13 and reported the cutoff values of CRP to be 7.065 mg/dl with 75.5% sensitivity and 96.5% specificity in patients with Grade 2 disease and 19.895 mg/dl with 73.9% sensitivity and 75.5% specificity in patients with Grade III disease, respectively [25]. Beliaev et al. evaluated the serum CRP level and NLR as a marker for the diagnosis of AC and prediction of the disease severity based on pathological findings, and they confirmed that CRP and NLR were superior to WBC in discriminative ability [1,26].

Although there are studies showing an association between the serum inflammatory markers such as CRP and WBC and disease severity in AC patients in the literature, there is no data about these markers and their relationship with the medical treatment response, treatment duration, and length of the hospital stay. In this study, we found that WBC and CRP levels are significantly associated with the treatment duration in AC patients with conservative treatment. The limitation of this study was its retrospective design and a low number of patients.

Conclusions

In conclusion, although TG 18 recommends early laparoscopic cholecystectomy in patients with AC if the patient is suitable for surgery, conservative treatment can be seen as an option in the treatment modality of these patients. We found that CRP level is associated with the treatment duration and hospital stay in AC patients. However, our study is a retrospective and single-center study with relatively small sample size; therefore, large-scale, prospective, further studies are needed to confirm our results and to determine if CRP levels can be used to discriminate which patient would benefit from medical treatment.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Ordu Üniversitesi Klinik Araştırmalar Etik Kurul issued approval 2020/198. This clinical study was approved by the Ethical Committee. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Beliaev AM, Angelo N, Booth M, Bergin C: Evaluation of neutrophil-to-lymphocyte ratio as a potential biomarker for acute cholecystitis. *J Surg Res.* 2017, 209:93-101. [10.1016/j.jss.2016.09.034](https://doi.org/10.1016/j.jss.2016.09.034)
2. Ahmed SE, Rehman S, Edilbe M, Jonker L, Canelo R: Can neutrophil-lymphocyte ratio predict operators' difficulty in early cholecystectomies; a retrospective cohort study. *Ann Emerg Surg.* 2017, 2:1016.
3. Okamoto K, Takada T, Strasberg SM, et al.: TG13 management bundles for acute cholangitis and cholecystitis. *J Hepatobiliary Pancreat Sci.* 2013, 20:55-9. [10.1007/s00534-012-0562-2](https://doi.org/10.1007/s00534-012-0562-2)
4. Gregory GC, Kuzman M, Sivaraj J, Navarro AP, Cameron IC, Irving G, Gomez D: C-reactive protein is an independent predictor of difficult emergency cholecystectomy. *Cureus.* 2019, 11:e4573. [10.7759/cureus.4573](https://doi.org/10.7759/cureus.4573)
5. Okamoto K, Suzuki K, Takada T, et al.: Tokyo guidelines 2018: flowchart for the management of acute cholecystitis. *J Hepatobiliary Pancreat Sci.* 2018, 25:55-72. [10.1002/jhbp.516](https://doi.org/10.1002/jhbp.516)
6. Micić D, Stanković S, Lalić N, Đukić V, Polovina S: Prognostic value of preoperative neutrophil-to-lymphocyte ratio for prediction of severe cholecystitis. *J Med Biochem.* 2018, 37:121-7. [10.1515/jomb-2017-0063](https://doi.org/10.1515/jomb-2017-0063)
7. Nikfarjam M, Niumsawatt V, Sethu A, et al.: Outcomes of contemporary management of gangrenous and non-gangrenous acute cholecystitis. *HPB (Oxford).* 2011, 13:551-8. [10.1111/j.1477-2574.2011.00327.x](https://doi.org/10.1111/j.1477-2574.2011.00327.x)
8. Kiriya S, Kozaka K, Takada T, et al.: Tokyo guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). *J Hepatobiliary Pancreat Sci.* 2018, 25:17-30. [10.1002/jhbp.512](https://doi.org/10.1002/jhbp.512)
9. Peery AF, Crockett SD, Barritt AS, et al.: Burden of gastrointestinal, liver, and pancreatic diseases in the

- United States. *Gastroenterology*. 2015, 149:1731-1741.e3. [10.1053/j.gastro.2015.08.045](https://doi.org/10.1053/j.gastro.2015.08.045)
10. Turiño SY, Shabanzadeh DM, Eichen NM, Jørgensen SL, Sørensen LT, Jørgensen LN: Percutaneous cholecystostomy versus conservative treatment for acute cholecystitis: a cohort study. *J Gastrointest Surg*. 2019, 23:297-303. [10.1007/s11605-018-4021-5](https://doi.org/10.1007/s11605-018-4021-5)
 11. Loozen CS, Oor JE, van Ramshorst B, van Santvoort HC, Boerma D: Conservative treatment of acute cholecystitis: a systematic review and pooled analysis. *Surg Endosc*. 2017, 31:504-15. [10.1007/s00464-016-5011-x](https://doi.org/10.1007/s00464-016-5011-x)
 12. Agrawal R, Sood KC, Agarwal B: Evaluation of early versus delayed laparoscopic cholecystectomy in acute cholecystitis. *Surg Res Pract*. 2015, 2015:349801. [10.1155/2015/349801](https://doi.org/10.1155/2015/349801)
 13. Gutt CN, Encke J, Königer J, et al.: Acute cholecystitis: early versus delayed cholecystectomy, a multicenter randomized trial (ACDC study, NCT00447304). *Ann Surg*. 2013, 258:385-93. [10.1097/SLA.0b013e3182a1599b](https://doi.org/10.1097/SLA.0b013e3182a1599b)
 14. Yokoe M, Takada T, Strasberg SM, et al.: New diagnostic criteria and severity assessment of acute cholecystitis in revised Tokyo guidelines. *J Hepatobiliary Pancreat Sci*. 2012, 19:578-85. [10.1007/s00534-012-0548-0](https://doi.org/10.1007/s00534-012-0548-0)
 15. Asai K, Watanabe M, Kusachi S, et al.: Bacteriological analysis of bile in acute cholecystitis according to the Tokyo guidelines. *J Hepatobiliary Pancreat Sci*. 2012, 19:476-86. [10.1007/s00534-011-0463-9](https://doi.org/10.1007/s00534-011-0463-9)
 16. Sproston NR, Ashworth JJ: Role of C-reactive protein at sites of inflammation and infection. *Front Immunol*. 2018, 9:754. [10.3389/fimmu.2018.00754](https://doi.org/10.3389/fimmu.2018.00754)
 17. Dolan RD, Lim J, McSorley ST, Horgan PG, McMillan DC: The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: systematic review and meta-analysis. *Sci Rep*. 2017, 7:16717. [10.1038/s41598-017-16955-5](https://doi.org/10.1038/s41598-017-16955-5)
 18. Ishizuka M, Shimizu T, Kubota K: Neutrophil-to-lymphocyte ratio has a close association with gangrenous appendicitis in patients undergoing appendectomy. *Int Surg*. 2012, 97:299-304. [10.9738/CC161.1](https://doi.org/10.9738/CC161.1)
 19. Namiuchi S, Sugie T, Saji K, Takii T, Suda A, Kato A: The systemic inflammation-based glasgow prognostic score as a prognostic factor in patients with acute heart failure. *J Cardiovasc Med (Hagerstown)*. 2015, 16:409-15. [10.2459/JCM.0000000000000184](https://doi.org/10.2459/JCM.0000000000000184)
 20. Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, Park M: C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. *PLoS One*. 2013, 8:e59321. [10.1371/journal.pone.0059321](https://doi.org/10.1371/journal.pone.0059321)
 21. Vigushin DM, Pepys MB, Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. *J Clin Invest*. 1993, 91:1351-7. [10.1172/JCI116336](https://doi.org/10.1172/JCI116336)
 22. Mok KW, Reddy R, Wood F, Turner P, Ward JB, Pursnani KG, Date RS: Is C-reactive protein a useful adjunct in selecting patients for emergency cholecystectomy by predicting severe/gangrenous cholecystitis?. *Int J Surg*. 2014, 12:649-53. [10.1016/j.ijssu.2014.05.040](https://doi.org/10.1016/j.ijssu.2014.05.040)
 23. Juvonen T, Kiviniemi H, Niemela O, et al.: Diagnostic accuracy of ultrasonography and C reactive protein concentration in acute cholecystitis: a prospective clinical study. *Eur J Surg*. 1992, 158:365-9.
 24. Sato N, Kinoshita A, Imai N, et al.: Inflammation-based prognostic scores predict disease severity in patients with acute cholecystitis. *Eur J Gastroenterol Hepatol*. 2018, 30:484-9. [10.1097/MEG.0000000000001063](https://doi.org/10.1097/MEG.0000000000001063)
 25. Gurbulak EK, Gurbulak B, Akgun IE, Duzkoylu Y, Battal M, Celayir MF, Demir U: Prediction of the grade of acute cholecystitis by plasma level of C-reactive protein. *Iran Red Crescent Med J*. 2015, 17:e28091. [10.5812/ircmj.17\(4\)2015.28091](https://doi.org/10.5812/ircmj.17(4)2015.28091)
 26. Beliaev AM, Marshall RJ, Booth M: C-reactive protein has a better discriminative power than white cell count in the diagnosis of acute cholecystitis. *J Surg Res*. 2015, 198:66-72. [10.1016/j.jss.2015.05.005](https://doi.org/10.1016/j.jss.2015.05.005)